Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06286709 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

FAecal Microbiota Transplantation in primaRy sclerosinG chOlangitis

Study acronym: FARGO
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 5 months later Apr 30, 2026 → Sep 30, 2027
See other at-risk trials from University of Birmingham

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Apr 30, 2026 to Sep 30, 2027 Show 5 more changesShow less
    • Study completion pushed from Feb 28, 2027 to Sep 30, 2027
    • Eligibility criteria expanded, about 33 words
    • Secondary endpoints: details revised at 3 of 19 entries
    • Site details revised at 2 of 5 sites
    • Publications: details revised at 1 of 1 entry
  2. Study completion date: Jul 29, 2026 to Feb 28, 2027
    • Site details revised at 1 of 5 sites
    v4
  3. Study sites: 6 to 5
    • Eligibility criteria expanded, about 35 words
    v3
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Feb 29, 2024 to Mar 27, 2024
    • Site details revised at 6 of 6 sites
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
FARGO is a randomised, phase IIa, multi-centre, placebo-controlled trial to compare Faecal Microbiota Transplant (FMT) with placebo in patients with primary sclerosing cholangitis (PSC) and concomitant inflammatory bowel disease.
Trial Details
NCT Number NCT06286709
Lead Sponsor University of Birmingham
Collaborators: PSC Support, Life Arc
Conditions
(from sponsor)		 Primary Sclerosing Cholangitis, Inflammatory Bowel Diseases
Related terms Cholangitis, Sclerosing, Inflammatory Bowel Diseases
Enrollment 58 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov